In metastatic non-small cell lung cancer (NSCLC) without a targetable driver mutation, treatment selection among immune checkpoint inhibitor regimens is governed by tumor PD-L1 expression level, which stratifies patients into biomarker-defined subgroups (high, low, and negative expression) that predict differential benefit from single-agent immunotherapy versus immunotherapy combined with a chemotherapy backbone. The underlying principle is that PD-L1 expression serves as a predictive biomarker for immune checkpoint blockade efficacy, while combination chemo-immunotherapy broadens efficacy across the biomarker spectrum by pairing direct cytotoxic activity with immune-mediated tumor cell killing, situating this within oncologic biomarker-guided therapy selection and immuno-oncology treatment sequencing.
In metastatic non-small cell lung cancer (NSCLC) without a targetable driver mutation, treatment selection among immune checkpoint inhibitor regimens is governed by tumor PD-L1 expression level, whic…